JP2018523673A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523673A5
JP2018523673A5 JP2018507602A JP2018507602A JP2018523673A5 JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5 JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5
Authority
JP
Japan
Prior art keywords
hcab
pdgf
seq
amino acid
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018507602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/046595 external-priority patent/WO2017030909A1/en
Publication of JP2018523673A publication Critical patent/JP2018523673A/ja
Publication of JP2018523673A5 publication Critical patent/JP2018523673A5/ja
Pending legal-status Critical Current

Links

JP2018507602A 2015-08-14 2016-08-11 Ｐｄｇｆに対する重鎖のみ抗体 Pending JP2018523673A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205191P 2015-08-14 2015-08-14
US62/205,191 2015-08-14
US201662333772P 2016-05-09 2016-05-09
US62/333,772 2016-05-09
PCT/US2016/046595 WO2017030909A1 (en) 2015-08-14 2016-08-11 Heavy chain only antibodies to pdgf

Publications (2)

Publication Number Publication Date
JP2018523673A JP2018523673A (ja) 2018-08-23
JP2018523673A5 true JP2018523673A5 (OSRAM) 2019-08-22

Family

ID=56740535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507602A Pending JP2018523673A (ja) 2015-08-14 2016-08-11 Ｐｄｇｆに対する重鎖のみ抗体

Country Status (7)

Country Link
US (5) US10308711B2 (OSRAM)
EP (1) EP3334762A1 (OSRAM)
JP (1) JP2018523673A (OSRAM)
AU (1) AU2016307943A1 (OSRAM)
CA (1) CA2992788A1 (OSRAM)
HK (1) HK1254093A1 (OSRAM)
WO (1) WO2017030909A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2017020001A2 (en) * 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
PL223153B1 (pl) 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
EP1979379B1 (en) * 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
AU2007257692B2 (en) * 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
PL2274008T3 (pl) * 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
MY162825A (en) * 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2694153T3 (es) * 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-ErbB3 y usos de los mismos
US9428577B2 (en) * 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
CA2890483A1 (en) * 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
WO2017020001A2 (en) * 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2

Similar Documents

Publication Publication Date Title
JP2016504416A5 (OSRAM)
JP2018527327A5 (OSRAM)
JP2010528047A5 (OSRAM)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2020114218A5 (OSRAM)
JP2019515027A5 (OSRAM)
AU2011201340B2 (en) Novel anti-PIGF antibody
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
AU2013288641B2 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
JP2011504872A5 (OSRAM)
JP2013528607A5 (OSRAM)
JP2020515545A5 (OSRAM)
JP2017535285A5 (OSRAM)
JP2019510078A5 (OSRAM)
JP2017536414A5 (OSRAM)
JP2017534646A5 (OSRAM)
RU2014129316A (ru) Способы ингибирования глазного ангиогенеза
NZ574308A (en) Scfv antibodies which pass epithelial and/or endothelial layers
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2018510617A5 (OSRAM)
JP2012165745A5 (OSRAM)
JP2017515811A5 (OSRAM)
JP2018530574A5 (OSRAM)
HRP20251312T1 (hr) Poboljšana protutijela za il-6
JP2017534645A5 (OSRAM)